Combined measurement of plasma cell proliferative and apoptotic index in multiple myeloma defines patients with good and poor prognosis

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 44-48

  Minarik, Jiri ^a   Scudla, Vlastimil ^a   Ordeltova, Marta ^a   Pika, Tomas ^a   Bacovsky, Jaroslav ^a   Steinbach, Michael ^b   Kumar, Vipin ^b   Van Ness, Brian ^c  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b University of Minnesota   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apoptosis; Multiple myeloma; Prognosis; Proliferation

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CLONE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMA CELLS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 78650176422     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.04.015     Document Type: Article

References (27)

1. San Miguel J.F., Fonseca R., Greipp PR Prognostic factors and classification for multiple myeloma (contribution to clinical management). Myeloma biology and management 2004, 189-199. Elsevier Inc., Philadelphia. 3rd ed. J.S. Malpas, D.E. Bergsagel, R.A. Kyle, K.C. Anderson (Eds.).
2. Greipp P.R., Kumar S Plasma cell labeling index. Methods: molecular medicine. Multiple myeloma. Methods and protocols 2005, 25-35. Humana Press, Totowa, NJ. R.D. Brown, P.J. Ho (Eds.).
3. Witzig T.E., Greipp P.R., Therneau T., Greipp P.R. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 1999, 104:131-137.
4. Greipp P.R., Kyle R.A. Clinical, morphological and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma. Blood 1983, 62:166-171.
5. Boccadoro M., Gavarotti P., Fossati G., et al. Low plasma cell 3H thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol 1984, 58:689-696.
6. Greipp P.R., Witzig T.E., Gonchoroff N.J. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1). Am J Hematol 1985, 20:289-292.
7. Greipp P.R., Katzmann J.A., OóFallon M., Kyle R.A. Value of beta-2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988, 72:219-223.
8. Girino M., Riccardi A., Luoni R., Ucci G., Cuomo A. Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies. Acta Haematol 1991, 85:26-30.
9. Orfao A., García-Sanz R., Lopez-Berges M.C., et al. A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique. Cytometry 1994, 17:332-339.
10. San Miguel J.F., Garcia-Sanz R., Gonzales M., Orfao A. DNA cell content studies in multiple myeloma. Leuk Lymphoma 1996, 23:33-41.
11. Oancea M., Mani A., Hussein M.A., Almasan A. Apoptosis of multiple myeloma. Int J Hematol 2004, 80:224-231.
12. Scudla V., Ordeltova M., Bacovsky J., Vytrasova M., Horak P., Minarik J. The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Haematologica 2005, 90:1713-1714.
13. Kumar S., Timm M., Lacy M.Q., et al. Combining measurements of plasma cell apoptosis and proliferation in multiple myeloma identifies patients with poor survival. Blood 2005, 106. [abstract 3410].
14. Xu J.L., Lai R., Kinoshita T., Nakashima N., Nagasaka T., Proliferation apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002, 55:530-534.
15. Scudla V., Ordeltova M., Minarik J., Dusek L., Zemanova M., Bacovsky J. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma. Neoplasma 2006, 53:199-205.
16. Zemanova M., Scudla V., Adam Z., et al. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. Neoplasma 2008, 55:345-349.
17. Durie B.G. Staging and kinetics of multiple myeloma. Semin Oncol 1986, 13:300-309.
18. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757. International Myeloma Working Group.
19. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Cancer 1975, 36:842-854.
20. Greipp P.R., San Miguel J.F., Fonseca R., et al. Development of an International Prognostic Index (IPI) for myeloma: report of the International Myeloma Working Group. Hematol J 2003, 4:542-544.
21. Ordeltova M, Spidlova A, Scudla V. [Evaluation of plasma cell cycle S-phase (CD38/propidium iodide) using flow cytometry]. Hodnocení S-fáze buněčného cyklu (CD38/propidium iodidového indexu) myelomových plasmocytů s pomocí průtokové cytometrie. Diagnoza 1999;1:11-5 [Czech.].
22. Ordeltova M, Scudla V., Spidlova A, Tomanova D, Bacovsky J, Vytrasova M. [Evaluation of plasma cell apoptosis (annexin-V/CD138 index) by flow cytometry]. Hodnocení apoptózy myelomových plazmocytů (annexin V/CD138 indexu) metodou průtokové cytometrie. Hematol Transf 2002;2:499-508 [Czech.].
23. Bergsagel P.L., Kuehl WM The molecular biology of multiple myeloma. Myeloma biology and management 2004, 35-57. Elsevier Inc., Philadelphia. 3rd ed. J.S. Malpas, D.E. Bergsagel, R.A. Kyle, K.C. Anderson (Eds.).
24. Chen-Kiang S Multiple myeloma and plasma cells: cell cycle and apoptotic controls. Myeloma biology and management 2004, 21-33. Elsevier Inc., Philadelphia. 3rd ed. J.S. Malpas, D.E. Bergsagel, R.A. Kyle, K.C. Anderson (Eds.).
25. Minarik J., Scudla V., Bacovsky J., et al. Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma. Neoplasma 2010, 57:8-14.
26. Minarik J., Scudla V., Ordeltova M., Bacovsky J., Pika T., Langova K. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. Eur J Haematol 2009, 83:528-534.
27. Minarik J., Scudla V., Ordeltova M., Bacovsky J., Pika T., Langova K. Monitoring of plasma cell proliferative and apoptotic indices in the course of multiple myeloma. Leuk Lymphoma 2009, 50:1983-1991.